AmberGen, Inc. is a privately-held, Boston-area company founded in 1995 to commercialize pioneering photonic technology developed at Boston University’s Molecular Biophysics Laboratory and the Photonics Center. The company’s mission is to innovate in the area of therapeutics and diagnostics by solving key problems that limit progress in medicine. AmberGen’s approach combines patented techniques in proteomics and light-based control of biomolecules.

Research Grants 98 show all


$1.4M
2015

$1.9M
2016

$753.5K
2017

$1.9M
2018

$1.9M
2019

Patents 112show all

  • 70
    G01N - Investigating or analysing materials by determining their chemical or physical properties
  • 33
    C12P - Fermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture
  • 28
    C12Q - Measuring or testing processes involving enzymes, nucleic acids or microorganisms
  • 16
    C12N - Microorganisms or enzymes
  • 15
    C07H - Sugars
  • 13
    C07K - Peptides
  • 11
    A61K - Preparations for medical, dental, or toilet purposes
  • 9
    C07D - Heterocyclic compounds
  • 7
    B01J - Chemical or physical processes, e.g. catalysis or colloid chemistry
  • 6
    C07C - Acyclic or carbocyclic compounds

Contact Information

Watertown, MA
Watertown, MA 02472
United States

Overview

Total FundingEmployeesLast Funding DateStatus
unknownOperating